Q32 Bio (QTTB) news
Recent news
Q32 Bio Inc.: Clear Street initiates coverage with buy rating; price target $38
Clear Street has initiated coverage of Q32 Bio Inc. with a "buy" rating and a price target of $38 per share, citing the company’s recent capital-raising activities and strategic positioning in the biotechnology sector. The firm’s decision follows Q32 Bio’s $55 million private placement, which was…
AInvest Wire · Sep 29, 2026Pvt placement to provide North Immunology ~$180M gross proceeds
North Immunology has announced the completion of a private placement financing that is expected to generate approximately $180 million in gross proceeds. This capital infusion will support the company’s ongoing research and development initiatives, as well as its broader operational needs. The move…
AInvest Wire · Sep 17, 2026Q32 Bio appoints José Trevejo, M.D., Ph.D., as chief medical officer and Ellie Hershberger, Pharm.D., as chief development officer
AInvest Wire · Sep 14, 2026Q32 Bio Inc.: Wells Fargo cuts target price to $59 from $66
Q32 Bio Inc. (QTTB) has seen recent analyst activity, with Wells Fargo adjusting its price target for the stock. The firm reduced its target to $59 from $66, maintaining a "Buy" rating as of July 13, 2026. This adjustment reflects a revised outlook amid ongoing developments in the biotechnology…
AInvest Wire · Aug 6, 2026Q32 Bio Inc.: H.C. Wainwright raises target price to $36 from $13
AInvest Wire · Jul 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.